Sobi Updates Financial Forecast for 2025
In a significant announcement, Swedish Orphan Biovitrum AB (publ) (Sobi) has revised its full-year outlook for 2025, responding to impressive financial developments in the recent quarter. The company is set to share its third-quarter financial report soon, highlighting its commitment to transparency and communication with stakeholders about its performance and future prospects.
Impressive Revenue Growth Reported
Sobi's group revenue for the third quarter of 2025 reached SEK 7,776 million, showcasing a strong 21% increase compared to the same period in 2024 when adjusted for constant exchange rates. This growth can be attributed to the successful market performance of several Sobi products, with notable contributions from Altuvoct, Doptelet, and Gamifant.
Cost Management and Profitability
The company indicated that the adjusted EBITA margin for Q3 2025 was 47%. This improvement is largely due to disciplined cost management and an efficient approach toward research and development expenses. Sobi effectively realigned its selling, general, and administrative (SG&A) activities as they awaited a mid-2026 FDA review decision regarding the NASP biologics license application.
Year-to-Date Performance Overview
As of the end of Q3 2025, Sobi's year-to-date revenue stood at SEK 20,417 million, reflecting a 15% rise compared to the same timeframe in 2024. The adjusted EBITA margin for the year to date was reported at 40%, further emphasizing the company’s strengthened financial position.
Updated Revenue and Profit Outlook
Sobi has now set a revised revenue outlook for 2025, expecting a growth rate in the low double digits, a notable increase from the previous high-single-digit guidance. The adjusted EBITA margin is also expected to be in the mid-to-high 30s percentage of revenue, improving upon earlier estimates.
Implications of Vonjo Impairment
In its financial reporting, Sobi will recognize a non-cash impairment charge of SEK 6,612 million associated with the product and marketing rights for Vonjo. Despite this, the product is still anticipated to serve as a long-term growth driver. The company remains focused on advancing the Pacifica phase 3 study which aims to broaden its label authorization in the US and expand reach into key international markets.
Anticipated Third Quarter Report
The upcoming third-quarter results are expected to be released on October 20, 2025. Following this announcement, a conference call will be held to discuss the results and address inquiries from investors, analysts, and media representatives. This session will help clarify the details of Sobi’s financial trajectory as they continue navigating the complexities of the biopharma sector.
About Sobi
Sobi is a global biopharmaceutical company dedicated to innovating treatments and improving the lives of individuals living with rare diseases. With a workforce of approximately 1,900 employees around the world, Sobi is well positioned to pursue its strategic objectives and maintain growth in a competitive marketplace. In 2024, the company's revenue was reported at SEK 26 billion, underlining its expansion and influence in the biopharma industry. More information about Sobi and its commitment to patients and stakeholders can be found on their official website.
Frequently Asked Questions
1. What is Sobi's revised revenue outlook for 2025?
Sobi anticipates a low double-digit percentage growth in revenue for 2025.
2. How did Sobi perform in Q3 2025?
The company reported a revenue of SEK 7,776 million, a 21% increase compared to Q3 2024.
3. What is the adjusted EBITA margin for Q3 2025?
The adjusted EBITA margin was reported at 47% for Q3 2025.
4. How is Sobi managing costs?
Sobi has implemented disciplined cost control measures, particularly in research and development spending.
5. What is the future growth potential of Vonjo?
Despite the recognized impairment, Vonjo is expected to be a long-term growth driver for Sobi as it progresses through clinical studies.
